Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARV-471 plus everolimus in ER+/HER2- advanced breast cancer
NCT05501769Phase 1Completed
- Sponsor
- Arvinas
- Start
- Sep 2022
- Primary completion
- Jul 2024
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of vepdegestrant in breast cancer, sponsored by Arvinas. Primary endpoints: Dose Limiting Toxicities at 35 days, Recommended Phase 2 Dose at 35 days and 2 more. Started Sep 2022; status: completed.
02
Drugs
vepdegestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05501769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05501769.